Publications by authors named "Angelina Sontag"
Article Synopsis
- Fecal urgency, a symptom of Ulcerative Colitis (UC), was studied to understand its association with patient characteristics and treatment changes among 400 patients in the CorEvitas Inflammatory Bowel Disease Registry.
- The study classified patients into four groups based on their urgency status at enrollment and after 6 months, finding that those with persistent or changing urgency reported more comorbidities and had worse overall health outcomes.
- Results indicated that patients experiencing urgency were more likely to change treatments within the 6-month follow-up, suggesting urgency may indicate inadequate therapy and negatively impacts quality of life.
Background: To evaluate disease burden and patient-reported outcomes (PROs) of ulcerative colitis (UC) patients at enrollment into CorEvitas' Inflammatory Bowel Disease Registry by therapy class.
Methods: Between May 3, 2017 and September 3, 2019, 773 UC registry patients were categorized by therapy class at enrollment: patients on 5-aminosalicylic acids (5-ASAs) only ( = 290), and patients on biologics/Janus kinase inhibitors (JAKi) alone or in combination with 5-ASAs or immunosuppressant therapies (BIO/JAKi) ( = 315). To quantify between group differences, the mean/proportional differences and corresponding 95% CIs were calculated.
Background: Baricitinib, a selective Janus kinase (JAK)1/JAK2 inhibitor, is approved for treatment of moderate-to-severe atopic dermatitis (AD) in adults.
Objectives: We report integrated baricitinib safety data in patients with up to 3.9-years exposure.
Article Synopsis
- The study assessed the effectiveness and safety of mirikizumab, an interleukin-23 inhibitor, in adult patients with moderate-to-severe plaque psoriasis over 52 weeks in a phase III trial known as OASIS-1.
- Results showed that at week 16, mirikizumab significantly outperformed placebo in achieving key psoriasis response metrics (69.3% vs. 6.5% for sPGA and 64.3% vs. 6.5% for PASI 90), indicating high efficacy.
- By week 52, mirikizumab maintained strong response rates across different dosing regimens, with safety profiles similar to placebo, suggesting it
Background: Survival outcomes are related to treatment choices in a line of therapy and to treatment sequences across all lines of therapy.
Objective: The Real-World Treatment Sequences and Outcomes among Patients with NSCLC (RESOUNDS) study is designed to (1) evaluate treatment sequences used for patients who receive at least two lines of therapy for non-small cell lung cancer (NSCLC) in the United States and (2) evaluate patient outcomes in terms of progression-free and overall survival related to treatment sequencing. Additional objectives include the evaluation of symptoms, comorbidities, and health care resource utilization and costs.
Purpose: Tadalafil once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia consistently shows statistically significant I-PSS improvements. However, physicians and patients wish to know whether tadalafil provides rapid, clinically meaningful improvement in lower urinary tract symptoms. In this post hoc analysis we integrated results from 4 placebo controlled studies to determine the duration of tadalafil once daily required to achieve clinically meaningful improvement.
View Article and Find Full Text PDFObjectives: To assess treatment satisfaction with tadalafil or tamsulosin vs placebo in a 12-week, randomised, double-blind study of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH).
Patients And Methods: After a 4-week placebo lead-in period, men aged ≥45 years with an International Prostate Symptom Score (IPSS) of ≥13 and a maximum urinary flow rate of ≥4 to ≤15 mL/s received placebo (172 men), tadalafil 5 mg (171), or tamsulosin 0.4 mg (168) once daily for 12 weeks.
Introduction: Despite widespread use of the International Index of Erectile Function (IIEF) in erectile dysfunction (ED) research, there are no published criteria for classifying ED treatment responders in clinical trials or patient management settings. A new classification for treatment response in men with ED has been developed and validated in a large clinical trial database.
Aim: The study aims to test discriminant and convergent validity of the responder classification and examine the role of covariates.
Introduction: Reliability of successful outcomes in men with erectile dysfunction (ED) on phosphodiesterase type 5 inhibitors is an important aspect of patient management.
Aims: We examined reliability of successful outcomes in a large integrated dataset of randomized tadalafil trials.
Main Outcome Measures: Success rates, time to success, subsequent success after first success, and probability of success were analyzed based on Sexual Encounter Profile questions 2 and 3.
Objective: To characterize the estimated risk of invasive breast cancer (IBC) in postmenopausal women without a family history of breast cancer (FHBC), baseline risk scores were calculated using the Breast Cancer Risk Assessment tool. We also analyzed the incidence rates of IBC stratified by FHBC.
Methods: For the Continuing Outcomes Relevant to Evista (CORE) study population (n = 3,991; excluding women ≥86 y of age or with a history of ductal carcinoma in situ or lobular carcinoma in situ), the prevalence of risk factors to the overall IBC risk was calculated.
After the occurrence of the first fracture, osteoporosis is no longer a "silent" disease, and the patient's risk for future fracture is increased several fold. We assessed the location of first osteoporotic fractures among women with osteoporosis. The Multiple Outcomes of Raloxifene Evaluation (MORE) trial was a fracture outcomes study of postmenopausal women with osteoporosis.
View Article and Find Full Text PDFObjective: Women without versus those with vertebral fracture may have different benefits and risks during raloxifene treatment. Our objective was to compare the effects of raloxifene to decrease risk for vertebral fracture and invasive breast cancer with its effect to increase risk for venous thromboembolism in postmenopausal women without or with baseline vertebral fracture.
Research Design And Methods: The Multiple Outcomes of Raloxifene Evaluation trial included postmenopausal women with osteoporosis randomized to placebo, raloxifene 60 mg/day, or raloxifene 120 mg/day for 4 years.